APA (7th ed.) Citation

Chida, K., Kotani, D., Moriwaki, T., Fukuoka, S., Masuishi, T., Takashima, A., . . . Shimada, Y. (2021). Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS). Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Chida, Keigo, et al. Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS). Frontiers Media S.A, 2021.

MLA (9th ed.) Citation

Chida, Keigo, et al. Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS). Frontiers Media S.A, 2021.